

| Parameter Statistic | Treatment Group Comparisons | | | | | | | | | |
|--|--|-------------------------|---|-------------------------|---|-------------------------|---|-------------------------|---|-------------------------|
| | Sparsentan, Pooled (200 mg, 400 mg, and 800 mg) to Irbesartan 300 mg | | Sparsentan, Pooled (400 mg and 800 mg) to Irbesartan 300 mg | | Sparsentan 400 mg to Irbesartan 300 mg | | Sparsentan 800 mg to Irbesartan 300 mg | | Sparsentan 200 mg to Irbesartan 300 mg | |
| | Irbesartan (n=32) | Sparsentan (n=64) | Irbesartan (n=25) | Sparsentan (n=51) | Irbesartan (n=17) | Sparsentan (n=21) | Irbesartan (n=8) | Sparsentan (n=30) | Irbesartan (n=7) | Sparsentan (n=13) |
| Baseline UP/C (g/g) | | | | | | | | | | |
| n | 32 | 64 | 25 | 51 | 17 | 21 | 8 | 30 | 7 | 13 |
| Mean | 4.017 | 4.707 | 3.816 | 4.824 | 3.482 | 4.749 | 4.526 | 4.876 | 4.734 | 4.248 |
| (SD) | (2.6717) | (3.7810) | (2.7160) | (4.0506) | (2.6074) | (4.1696) | (2.9842) | (4.0362) | (2.5701) | (2.5304) |
| Median | 3.265 | 3.620 | 2.970 | 3.530 | 2.850 | 3.710 | 3.295 | 3.225 | 4.860 | 3.710 |
| Min, Max | 0.88, 10.73 | 0.43, 18.66 | 0.88, 10.73 | 0.43, 18.66 | 1.10, 10.73 | 1.25, 18.66 | 0.88, 9.76 | 0.43, 14.68 | 0.98, 8.03 | 1.50, 10.15 |
| Week 8 UP/C (g/g) | | | | | | | | | | |
| n | 32 | 64 | 25 | 51 | 17 | 21 | 8 | 30 | 7 | 13 |
| Mean | 3.164 | 3.300 | 2.990 | 3.208 | 2.795 | 2.452 | 3.405 | 3.737 | 3.786 | 3.663 |
| (SD) | (2.2713) | (3.5719) | (2.3598) | (3.4738) | (2.4581) | (2.6254) | (2.2343) | (3.9177) | (1.9501) | (4.0650) |
| Median | 2.405 | 1.980 | 2.390 | 1.900 | 2.380 | 1.730 | 3.020 | 2.085 | 3.640 | 2.060 |
| Min, Max | 0.43, 10.19 | 0.12, 14.47 | 0.43, 10.19 | 0.12, 14.47 | 0.43, 10.19 | 0.28, 12.34 | 1.11, 8.37 | 0.12, 14.47 | 1.45, 6.69 | 0.59, 14.38 |
| Percentage Change from Baseline to Week 8 (95% CI) ^a | -18.5 (-34.6, 1.7) | -44.8 (-52.7, -35.7) | -19.0 (-38.0, 5.9) | -47.4 (-56.3, -36.9) | -28.1 (-47.5, -1.6) | -52.7 (-64.3, -37.2) | -9.3 (-45.3, 50.3) | -41.3 (-54.4, -24.4) | -15.0 (-41.8, 24.2) | -33.1 (-49.3, -11.6) |
| Ratio (sparsentan/ irbesartan) ^b (95% CI) | | 0.7 (0.5, 0.9) | | 0.6 (0.5, 0.9) | | 0.7 (0.4, 1.0) | | 0.6 (0.4, 1.1) | | 0.8 0.5, 1.3 |
| p-value ^c | --- | 0.006 | --- | 0.011 | --- | 0.056 ^d | --- | 0.127 ^d | --- | 0.298 ^d |

Abbreviations: ANCOVA = analysis of covariance; CI = confidence interval; LS = least squares; Max = maximum; Min = minimum; SD = standard deviation; UP/C = urine protein to creatinine ratio ; UPE = urinary protein excretion

a Geometric least squares mean, calculated as $[\exp(\text{LS mean change from baseline in natural log(UP/C)}) - 1] \times 100$. The same transformation was applied to obtain the corresponding 95% CI.

b Ratio (sparsentan/irbesartan) = $\exp[\text{LS mean change from baseline in natural log(UPE) for sparsentan} - \text{LS mean change from baseline in natural log(UPE) for irbesartan}]$. The same transformation is applied to obtain corresponding 95% CI for the ratio (sparsentan/irbesartan).

c p-value is the treatment effect p-value from the ANCOVA model. An ANCOVA model was fitted with the change in natural log(UP/C) from baseline as the dependent variable, treatment and cohort as the main effects, and baseline natural log(UP/C) as a covariate.

d Nominal p-value.

Source: Table 14.2.1.1.1 15AUG2019; Table 14.2.1.2.1 15AUG2019; Table 14.2.1.3.1 15AUG2019; Table 14.2.1.4.1 15AUG2019; Table 14.2.1.5.1 15AUG2019